Journal of Pain and Symptom Management
Volume 39, Issue 2 , Pages 186-196 , February 2010

Neuroleptic Dose in the Management of Delirium in Patients with Advanced Cancer

  • David Hui, MD, MSc, FRCPC

      Affiliations

    • Department of Palliative Care & Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Shirley H. Bush, MBBS, MRCGP, FAChPM

      Affiliations

    • Department of Palliative Care & Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    • McCulloch House, Southern Health Care Network, Melbourne, Victoria, Australia
    • Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia
    • ,
  • Laura E. Gallo, MD

      Affiliations

    • Department of Palliative Care & Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • J. Lynn Palmer, PhD

      Affiliations

    • Department of Palliative Care & Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Sriram Yennurajalingam, MD

      Affiliations

    • Department of Palliative Care & Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Eduardo Bruera, MD

      Affiliations

    • Department of Palliative Care & Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    • Corresponding Author InformationAddress correspondence to: Eduardo Bruera, MD, Department of Palliative Care & Rehabilitation Medicine, Unit 008, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

,Accepted 15 July 2009.

References 

  1. Breitbart W, Strout D. Delirium in the terminally ill. Clin Geriatr Med. 2000;16:357–372
  2. Centeno C, Sanz A, Bruera E. Delirium in advanced cancer patients. Palliat Med. 2004;18:184–194
  3. Lawlor PG, Bruera ED. Delirium in patients with advanced cancer. Hematol Oncol Clin North Am. 2002;16:701–714
  4. Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160:786–794
  5. Breitbart W, Bruera E, Chochinov H, Lynch M. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage. 1995;10:131–141
  6. Bruera E, Miller L, McCallion J, et al. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage. 1992;7:192–195
  7. Gagnon B, Lawlor PG, Mancini IL, et al. The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients. J Pain Symptom Manage. 2001;22:826–833
  8. Francis J, Kapoor WN. Prognosis after hospital discharge of older medical patients with delirium. J Am Geriatr Soc. 1992;40:601–606
  9. Attard A, Ranjith G, Taylor D. Delirium and its treatment. CNS Drugs. 2008;22:631–644
  10. Fang CK, Chen HW, Liu SI, et al. Prevalence, detection and treatment of delirium in terminal cancer inpatients: a prospective survey. Jpn J Clin Oncol. 2008;38:56–63
  11. Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium. CD005594 Cochrane Database Syst Rev. 2007;(2):
  12. Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother. 2006;40:1966–1973
  13. Inouye SK. Delirium in older persons. N Engl J Med. 2006;354:1157–1165
  14. Akechi T, Uchitomi Y, Okamura H, et al. Usage of haloperidol for delirium in cancer patients. Support Care Cancer. 1996;4:390–392
  15. Olofsson SM, Weitzner MA, Valentine AD, Baile WF, Meyers CA. A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support Care Cancer. 1996;4:351–357
  16. Breitbart W, Chochinov HM, Passik SD. Psychiatric symptoms in palliative medicine. In:  Doyle D,  Hanks G,  Cherny NI,  Calman K editor. Oxford textbook of palliative medicine. 3rd ed.. New York: Oxford University Press; 2004;p. 746–771
  17. Bruera E, Bush SH, Willey J, et al. The impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer. 2009;9:2004–2012
  18. Breitbart W, Rosenfeld B, Roth A, et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997;13:128–137
  19. Rijcken CA, Monster TB, Brouwers JR, de Jong-van den Berg LT. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses?. J Clin Psychopharmacol. 2003;23:657–659
  20. WHO Collaborating Centre for Drug Statistics Methodology . Available from: http://www.whocc.no/atcddd/Accessed November 12, 2008
  21. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  22. Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics. 2002;43:183–194
  23. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996;153:231–237
  24. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004;45:297–301
  25. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs. haloperidol: treating delirium in a critical care setting. Intensive Care Med. 2004;30:444–449
  26. Casarett DJ, Inouye SK American College of Physicians-American Society of Internal Medicine End-of-Life Care Consensus Panel. Diagnosis and management of delirium near the end of life. Ann Intern Med. 2001;135:32–40
  27. Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med. 1994;22:433–440
  28. Nakamura J, Uchimura N, Yamada S, Nakazawa Y. Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. Int Clin Psychopharmacol. 1997;12:147–152
  29. Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics. 1998;39:422–430
  30. Schwartz TL, Masand PS. Treatment of delirium with quetiapine. Prim Care Companion J Clin Psychiatry. 2000;2:10–12
  31. Hu H, Deng W, Yang H. A prospective random control study comparison of olanzapine and haloperidol in senile delirium. Chongging Med J. 2004;8:1234–1237
  32. Kim JY, Jung IK, Han C, et al. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry Clin Neurosci. 2005;59:183–188
  33. Cohen IL. Management of the agitated intensive care unit patient. Crit Care Med. 2002;30(1 Suppl A):S97–S123
  34. Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med. 2004;18:195–201

 Drs. Hui and Bush contributed equally to this study. Dr. Bruera is supported in part by National Institutes of Health grant numbers RO1NR010162-01A1, RO1CA122292-01, and RO1CA124481-01. Dr. Hui is funded by a fellowship from the Clinician Investigator Program, Royal College of Physicians and Surgeons of Canada.

PII: S0885-3924(09)01139-7

doi: 10.1016/j.jpainsymman.2009.07.009

Journal of Pain and Symptom Management
Volume 39, Issue 2 , Pages 186-196 , February 2010

Article Tools